预测潜在的重磅炸弹药物(6)
这些关切影响了对销售额的预测，它一度被估计可达每年40亿美元，现在则跌至最高约15亿美元，有些分析师甚至一路下调至数亿美元。Decision Resources公司预计Gilead公司的quad到2018年巅峰收入将可达到25亿美元。而评估机构Stifel Nicolaus分析师Maged Shenouda估计，如果quad在2012年获批准，至2015年它的形式峰值将达8亿美元。
注：本文所用中文商品名和通用名中注有“*”者为参考名，其余为国内注册名或(个别)约定俗成名。
参考文献
[1] Carroll J， McBride R. 15 top blockbuster contenders[OL]. [2011-10-25].http://www.fiercebiotech.com/special-reports/top-15-blockbuster-contenders.
, 百拇医药
[2] Stein EA, Roth EM, Rhyne JM, et al. Safety and tolerability of dalcetrapib (RO4607381/JTT-705): results from a 48-week trial[J]. Eur Heart J. 2010， 31 (4): 480–8.
[3] Carroll J. Roche HDL drug dalcetrapib clears a crucial safety test[OL]. [2011-10-25]. http://www.fiercebiotech.com/story/roche-hdl-drug-dalcetrapib-clears-crucial-safety-test/2011-08-28.
[4] Kresge N. Roche Seeks $6.8 Billion[OL]. [2011-8-19] .http://www.bloomberg.com/news/2011-08-19/roche-seeks-6-8-billion-win-on-heart-pill-where-pfizer-failed.html.
, 百拇医药
[5] Alzheimersweekly. Bapineuzumab Extends Clinical Trials[OL]. http://alzheimersweekly.com/content/bapineuzumab-extends-clinical-trials.
[6] Steenhuysen J. Groups convince FDA to ease Alzheimer’s trial rules[OL]. [2011-7-11].http://www.dementiatoday.net/article/groups-convince-fda-to-ease-alzheimers-trial-rules/.
[7] Decision resources . The alzheimer’s disease drug market will nearly triple over the next ten years， increasing from $5.4 billion in 2010 to $14.3 billion in 2020[OL]. [2011-10-6]. http://decisionresources.com/News-and-Events/Press-Releases/Alzheimers-Disease-100611.
, http://www.100md.com
[8] Connolly SJ， Eikelboom J， Joyner C， et al. Apixaban in patients with atrial fibrillation[J]. N. Engl. J. Med. 2011， 364 (9): 806–17.
[9] Alexander JH， Lopes RD， James S， et al. Apixaban with antiplatelet therapy after acute coronary syndrome[J]. N. Engl. J. Med. 2011，365 (8): 699–708.
[10] Bristol-Myers Squibb . Apixaban for the prevention of stroke in subjects with atrial fibrillation (aristotle) [OL]. [2011-6-23]. http://clinicaltrials.gov/ct2/show/study/NCT00412984?term=apixaban+aristotle&rank=112.
, 百拇医药
[11] Granger CB， Alexander JH， McMurray JJV， et al. Apixaban versus warfarin in patients with atrial fibrillation[J]. N Engl J Med. 2011， 365(11):981-992.
[12] Husten L. ELIQUIS® (apixaban) meets primary and key secondary endpoints in phase 3 aristotle study[OL].[2011-06-22]. CardioBrief. WordPress.com. http://cardiobrief.org/2011/06/22/apixaban-eliquis-meets-primary-endpoint-in-aristotle/.
[13] Keller DM. Bardoxolone improves kidney function in CKD out to 1 year[OL]. [2011-6-24]. http://www.medscape.com/viewarticle/745260.
, 百拇医药
[14] Bayer Schering Pharma AG. Xarelto: summary of product characteristics[OL]. [2009-2-19]. http://www.xarelto.com/scripts/pages/en/information-on-xarelto/summary_of_product_characteristics/index.php.
[15] Janssen Pharmaceutica. FDA approves XARELTO® (rivaroxaban tablets) to help prevent deep vein thrombosis in patients undergoing knee or hip replacement surgery (Press release) [OL]. [2011-7-1]. http://m.prnewswire.com/news-releases/fda-approves-xarelto-rivaroxaban-tablets-to-help-prevent-deep-vein-thrombosis-in-patients-undergoing-knee-or-hip-replacement-surgery-124872829.html., http://www.100md.com(李敏华 许关煜)
注：本文所用中文商品名和通用名中注有“*”者为参考名，其余为国内注册名或(个别)约定俗成名。
参考文献
[1] Carroll J， McBride R. 15 top blockbuster contenders[OL]. [2011-10-25].http://www.fiercebiotech.com/special-reports/top-15-blockbuster-contenders.
, 百拇医药
[2] Stein EA, Roth EM, Rhyne JM, et al. Safety and tolerability of dalcetrapib (RO4607381/JTT-705): results from a 48-week trial[J]. Eur Heart J. 2010， 31 (4): 480–8.
[3] Carroll J. Roche HDL drug dalcetrapib clears a crucial safety test[OL]. [2011-10-25]. http://www.fiercebiotech.com/story/roche-hdl-drug-dalcetrapib-clears-crucial-safety-test/2011-08-28.
[4] Kresge N. Roche Seeks $6.8 Billion[OL]. [2011-8-19] .http://www.bloomberg.com/news/2011-08-19/roche-seeks-6-8-billion-win-on-heart-pill-where-pfizer-failed.html.
, 百拇医药
[5] Alzheimersweekly. Bapineuzumab Extends Clinical Trials[OL]. http://alzheimersweekly.com/content/bapineuzumab-extends-clinical-trials.
[6] Steenhuysen J. Groups convince FDA to ease Alzheimer’s trial rules[OL]. [2011-7-11].http://www.dementiatoday.net/article/groups-convince-fda-to-ease-alzheimers-trial-rules/.
[7] Decision resources . The alzheimer’s disease drug market will nearly triple over the next ten years， increasing from $5.4 billion in 2010 to $14.3 billion in 2020[OL]. [2011-10-6]. http://decisionresources.com/News-and-Events/Press-Releases/Alzheimers-Disease-100611.
, http://www.100md.com
[8] Connolly SJ， Eikelboom J， Joyner C， et al. Apixaban in patients with atrial fibrillation[J]. N. Engl. J. Med. 2011， 364 (9): 806–17.
[9] Alexander JH， Lopes RD， James S， et al. Apixaban with antiplatelet therapy after acute coronary syndrome[J]. N. Engl. J. Med. 2011，365 (8): 699–708.
[10] Bristol-Myers Squibb . Apixaban for the prevention of stroke in subjects with atrial fibrillation (aristotle) [OL]. [2011-6-23]. http://clinicaltrials.gov/ct2/show/study/NCT00412984?term=apixaban+aristotle&rank=112.
, 百拇医药
[11] Granger CB， Alexander JH， McMurray JJV， et al. Apixaban versus warfarin in patients with atrial fibrillation[J]. N Engl J Med. 2011， 365(11):981-992.
[12] Husten L. ELIQUIS® (apixaban) meets primary and key secondary endpoints in phase 3 aristotle study[OL].[2011-06-22]. CardioBrief. WordPress.com. http://cardiobrief.org/2011/06/22/apixaban-eliquis-meets-primary-endpoint-in-aristotle/.
[13] Keller DM. Bardoxolone improves kidney function in CKD out to 1 year[OL]. [2011-6-24]. http://www.medscape.com/viewarticle/745260.
, 百拇医药
[14] Bayer Schering Pharma AG. Xarelto: summary of product characteristics[OL]. [2009-2-19]. http://www.xarelto.com/scripts/pages/en/information-on-xarelto/summary_of_product_characteristics/index.php.
[15] Janssen Pharmaceutica. FDA approves XARELTO® (rivaroxaban tablets) to help prevent deep vein thrombosis in patients undergoing knee or hip replacement surgery (Press release) [OL]. [2011-7-1]. http://m.prnewswire.com/news-releases/fda-approves-xarelto-rivaroxaban-tablets-to-help-prevent-deep-vein-thrombosis-in-patients-undergoing-knee-or-hip-replacement-surgery-124872829.html., http://www.100md.com(李敏华 许关煜)